WEKO3
インデックスリンク
アイテム
Mechanistic / mammalian target protein of rapamycin signaling in hematopoietic stem cells and leukemia
https://doi.org/10.24517/00027507
https://doi.org/10.24517/00027507911faa12-43fa-4376-8a09-cfb0011461bb
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
CA-PR-HIRAO-A-977.pdf (315.9 kB)
|
.png)
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2017-10-05 | |||||||||
| タイトル | ||||||||||
| タイトル | Mechanistic / mammalian target protein of rapamycin signaling in hematopoietic stem cells and leukemia | |||||||||
| 言語 | ||||||||||
| 言語 | eng | |||||||||
| 資源タイプ | ||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||
| 資源タイプ | journal article | |||||||||
| ID登録 | ||||||||||
| ID登録 | 10.24517/00027507 | |||||||||
| ID登録タイプ | JaLC | |||||||||
| 著者 |
Hirao, Atsushi
× Hirao, Atsushi× Hoshii, Takayuki |
|||||||||
| 著者別表示 |
平尾, 敦
× 平尾, 敦
× 星居, 孝之
|
|||||||||
| 提供者所属 | ||||||||||
| 内容記述タイプ | Other | |||||||||
| 内容記述 | がん進展制御研究所 | |||||||||
| 書誌情報 |
Cancer Science 巻 104, 号 8, p. 977-982, 発行日 2013-08-01 |
|||||||||
| ISSN | ||||||||||
| 収録物識別子タイプ | ISSN | |||||||||
| 収録物識別子 | 1347-9032 | |||||||||
| NCID | ||||||||||
| 収録物識別子タイプ | NCID | |||||||||
| 収録物識別子 | AA11808050 | |||||||||
| DOI | ||||||||||
| 関連タイプ | isIdenticalTo | |||||||||
| 識別子タイプ | DOI | |||||||||
| 関連識別子 | 10.1111/cas.12189 | |||||||||
| 出版者 | ||||||||||
| 出版者 | Japanese Cancer Association / Blackwell Publishing Ltd | |||||||||
| 抄録 | ||||||||||
| 内容記述タイプ | Abstract | |||||||||
| 内容記述 | Mechanistic/mammalian target protein of rapamycin (mTOR) is an evolutionarily conserved kinase that plays a critical role in sensing and responding to environmental determinants such as nutrient availability, energy sufficiency, stress, and growth factor concentration. mTOR participates in two complexes, designated mTOR complex 1 (mTORC1) and 2 (mTORC2), both of which phosphorylate multiple substrates. Recent studies have revealed that the fine-tuning activity of mTOR complexes contributes to both maintenance of hematopoietic stem cells (HSCs) and suppression of leukemogenesis. Dysregulation of mTORC1 activity results in impaired HSC homeostasis. Abnormalities of mTOR signaling are observed in many patients with leukemia and genetic studies clearly show that the leukemogenesis associated with Pten deficiency involves both mTORC1 and mTORC2. Although the several mTOR inhibitors have been developed for cancer therapy, effectiveness of the inhibitors for eradication of leukemia stem cells (LSCs) is unknown. Advances in understanding of how mTOR signaling is involved in mechanisms of normal HSC and LSC homeostasis may lead to novel therapeutic approaches that can successfully eradicate leukemia. © 2013 Japanese Cancer Association. | |||||||||
| 権利 | ||||||||||
| 権利情報 | © Japanese Cancer Association 日本癌学会 | |||||||||
| 著者版フラグ | ||||||||||
| 出版タイプ | VoR | |||||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||||
| 関連URI | ||||||||||
| 識別子タイプ | URI | |||||||||
| 関連識別子 | http://www.jca.gr.jp/ | |||||||||
